Issue: June 25, 2021

Read more

April 18, 2021
1 min read
Save

Rutgers Cancer Institute of New Jersey appoints neuro-oncology program director

Issue: June 25, 2021
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Michael E. Salacz, MD, has been appointed director of the neuro-oncology program at Rutgers Cancer Institute of New Jersey.

Salacz also will serve as associate professor of medicine at Rutgers Robert Wood Johnson Medical School.

“I am excited to join New Jersey’s only NCI-designated comprehensive cancer center to bring advances to the field of neuro-oncology,” Salacz said in a press release. “I look forward to working with the team of physicians and scientists in the neuro-oncology program to continue the mission of improving outcomes for patients with brain and spinal tumors through improvements in diagnosis and treatment while providing patient-centered care, one patient at a time.”

Michael E. Salacz, MD
Michael E. Salacz

Salacz previously served as division chief of neuro-oncology and director of the brain and spine tumor program at University of Kansas Medical Center. He has more than 15 years of experience treating patients with central nervous system tumors.

“Dr. Salacz enhances Rutgers Cancer Institute’s already extensive expertise and services in treating patients with neurological cancers,” Deborah Toppmeyer, MD, chief medical officer and chief of medical oncology at Rutgers Cancer Institute of New Jersey, said in the release. “We look forward to his leadership as we continue to deliver the best care and experience for our patients.”